Adhesion molecule expression trigger immune-mediated pathology in lupus-nephritis

AJBM crossMark

Downloads: 346
Bassim Jens Boldron 1, Simon Caltabiano 1, Steven D. Debono 1, 2, Robert Thompson 1, Malcolm Scammells 1, Robert Westover 1, Ye Wu 1, 3, Philip Frugier *2 
Author Affiliations
∗Correspondence author e-mail:Philip.Frugier @qmail.com: 1Department of Internal Medicine, The Ohio State Wexner Medical Center, Ohio, USA, 2Centre for Inflammatory Diseases, Monash University Department of Medicine, Australia , 3Core Research Laboratory, School of Medicine, Xi'an Jiaotong University, Xi'an, China.

 

Abstract

Doxorubicin (Dox) is one of the most potent broad-spectrum antitumor anthracycline antibiotics, its use is limited by the development of life-threatening cardiomyopathy. Doxorubicin generates free radicals and induces oxidative stress associated with cellular injury. Further, it has been shown that free radicals are involved in doxorubicin-induced toxicity. The goal of this study is to investigated the cardio-protective effects of caffeic acid on doxorubicin induced cardiotoxicity. The rats were randomized into three equal groups, sham group without treatment, doxorubicin treated group at a dose 3mg/kg IP every other two days and group treated with doxorubicin plus caffeic acid 40mg/day. Two weeks later LV function measurment were performed and blood samples were collected from the heart to measurment plasma levels of cardiac Troponin-I (cTn-I), oxidative stress parameter malondialdehyde (MDA) and high a sensitive c-reactive protein (hs-CRP). The hearts were excised for cardiac tissue cytokines (TNF-α, IL-1ÎČ, IL-10) measurement and microscopic examination. Rats in the Dox+caffeic acid group had improved LV function, reduced cytokine expression, decreased myocardial marker injury (cTn-I) and less MDA, hs-CRP levels in comparison with the Dox group. Pathological finding appeared nearly normal in the Dox+caffeic acid without fibrosis. The results of the present study reveal that caffeic acid has a promising cardioprotective effect against doxorubicin-induced cardiotoxicity.

Keywords: Doxorubicin; Cardiotoxicity; Inflammatory response; Left ventricular function

Copyright © 2020 by The American Society for BioMedicine and BM-Publisher, Inc.

Article citationReferencesFull-Text/PDFBecome reviewer
The citation data is computed by the following citation measuring services:

Cited by (CrossRef)
Google Scholar

  1. Rekvig OP, Putterman C, Casu C, et al. Autoantibodies in lupus: culprits or passive bystanders? Autoimmun Rev 2012;11(8):596-603. [PubMed]
  2. Bae SC, Koh HK, Chang DK, et al. Reliability and validity of Systemic Lupus Activity Measure-Revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus 2001;10:405–9. [PubMed]
  3. Couser WC, Salant DJ, Madaio MP, et al. Factors influencing glomerular and tubulointerstitial patterns of injury in SLE. Am J Kidney Dis 1982;2:126–134. [PubMed]
  4. Underhill GH, Minges Wols HA, Fornek JL, et al. IgG plasma cells display a unique spectrum of leukocyte adhesion and homing molecules. Blood 2002;99:2905–2912. [PubMed]
  5. Takahashi S, Araki K, Araki M, et al. Suppression of experimental lupus nephritis by aberrant expression of the soluble E-selectin gene. Pathol Int 2002;52:175–180. [PubMed]
  6. Sires RL, Adler SG, Louie JS, Cohen AH. Poor prognosis in end-stage lupus nephritis due to nonautologous vascular access site associated septicemia and lupus flares. Am J Nephrol 1989;9(4):279-84. [PubMed]
  7. Chaussabel D, Quinn C, Shen J, et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 2008;29:150–64. [PubMed]
  8. Zameer A, Hoffman T. Increased ICAM-1 and VCAM-1 expression in the brains of autoimmune mice. Journal of Neuroimmunology 2003;142:67-74. [Abstract/FullText]
  9. Seelen MA, Trouw LA, Daha MR. Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Curr Opin Nephrol Hypertens 2003;12(6):619-24. [PubMed]
  10. Vasudevan A, Krishnamurthy AN. Changing worldwide epidemiology of systemic lupus erythematosus. Rheum Dis Clin North Am 2010;36(1):1-13. [PubMed]
  11. Deapen D, Escalante A, Weinrib L, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 1992;35:311–318. [PubMed]
  12. McCarty DJ, Manzi S, Medsger TA Jr, et al. Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum 1995;38:1260–1270. [PubMed]
  13. Dai Y, Sui W, Lan H, et al. Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int 2009;29:749–754. [PubMed]
  14. Dai Y, Huang YS, Tang M, et al. Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus 2007;16:939–946. [PubMed]
  15. Schiffer L, Kumpers P, Davalos-Misslitz AM, et al. B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE). Nephrol Dial Transplant  2009;24:3708–3712. [PubMed]
  16. Peterson KS, Huang JF, Zhu J, et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest 2004;113:1722–1733. [PubMed]
  17. Davies MJ, Gordon JL, Gearing AJ, et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 1993;171:223229. [PubMed]
  18. Villanueva E, Yalavarthi S, Berthier CC, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol  2011;187:538–552. [PubMed]
  19. Hill GS, Delahousse M, Nochy D, et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int 2001;59:304–316. [PubMed]
  20. Fismen S, Mortensen ES, Rekvig OP. Nuclease deficiencies promote end-stage lupus nephritis but not nephritogenic autoimmunity in (NZB x NZW) F1 mice. Immunol Cell Biol 2011;89:90–99. [PubMed]
  21. Collins RG, Velji R, Guevara NV, et al. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 2000;191:189–194. [PubMed]
  22. Jung GS, Kim MK, Jung YA, et al. Clusterin attenuates the development of renal fibrosis. J Am Soc Nephrol 2002;23:73–85. [PubMed]
  23. Torres R, de Castellarnau C, Ferrer LL, et al. Mast cells induce upregulation of P-selectin and intercellular adhesion molecule 1 on carotid endothelial cells in a new in vitro model of mast cell to endothelial cell communication. Immunol Cell Biol 2002;80:170–177. [PubMed]
  24. Tidball JG. Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol 2005;288:R345–353. [PubMed]
  25. W G James1, P Hutchinson, D C Bullard, M J Hickey. Cerebral leucocyte infiltration in lupus-prone MRL/MpJ-fas lpr mice--roles of intercellular adhesion molecule-1 and P-selectin. Clin Exp Immunol 2006;144(2):299-308.


READ THE FULL ARTICLE

For any technique error please contact us and will be response to sending purchase article by email.

Who Can Become a Reviewer?
Any expert in the article's research field can become a reviewer with American Journal of BioMedicine. Editors might ask you to look at a specific aspect of an article.

Find out more

Research Article
DOI: http://dx.doi.org/110.18081/ajbm/2333-5106-013-12/49-57
American Journal of BioMedicine Volume 2, Issue 1, pages 27-36
Received 02 September 2013; accepted 17 January 2014; published 22 February 2014

How to cite this article
Boldron J, Caltabiano S, Debono SD, Thompson R, Scammells M,Westover R, Wu Y, Frugier P. Adhesion molecule expression trigger immune-mediated pathology in lupus-nephritis. American Journal of BioMedicine 2014;2(1):27-36.

Case report outline
1. Abstract
2. Keywords
3. Introduction
4. Methods
5. Results
6. Discussion
7. References